Reference

Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers

Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Stockis, Armel; Gengler, Christophe; Goethals, Fabienne; Jeanbaptiste, Bernard; Lens, Simone; Poli, Gianluigi; Acerbi, Daniela ( SGS Biopharma S.A., Wavre, Belg.). Arzneimittel-Forschung, 53(9), 627-634 (English) 2003 Editio Cantor Verlag. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The objective of the study was to assess potential pharmacokinetic interactions between delapril, an angiotensin conversion enzyme inhibitor, and manidipine, a calcium channel antagonist, prior to the development of a fixed combination drug product. Eighteen healthy male volunteers received a single oral dose of 10 mg manidipine dihydrochloride (CAS 89226-75-5), or 30 mg delapril hydrochloride (CAS 83435-67-0), or both simultaneously, according to a fully balanced 3-way cross-over design. The 3 treatments were sepd. by a one-week washout period. Blood samples were collected during 24 h for plasma detn. of manidipine and metabolite M-XIII and/or of delapril and metabolites M1, M2 and M3, using specific LC-MS/MS methods. The bioavailability of manidipine and M-XIII was slightly decreased by concomitant administration of delapril (manidipine: Cmax - 19 % and AUC￥ - 11 %; M-XIII: Cmax - 17 % and AUCt - 18 %). The bioavailability of delapril was not influenced by co-administration with manidipine (Cmax -7 % and AUC￥ +4 %). The effect on delapril pharmacol. active metabolites M1 and M3 was negligible. The inactive metabolite M2 underwent a 13 % redn. of Cmax and AUC￥. The 90 % confidence intervals were confined within limits of acceptance (70-143 % for Cmax and 80-125 % for AUC). Mean residence times and apparent elimination half-lives were unaltered. Blood pressure and heart rate vs. time profiles were similar during the 3 treatments. Simultaneous oral administration of 10 mg manidipine and 30 mg delapril does not significantly alter the pharmacokinetics of either drug or that of their principal metabolites.

Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects

Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects. Stockis, Armel; De Bruyn, Steven; Gengler, Christophe; Goethals, Fabienne; Lens, Simone; Poli, Gianluigi; Acerbi, Daniela (SGS Biopharma S.A., Wavre, Belg.). Arzneimittel-Forschung, 53(8), 554-561 (English) 2003 Editio Cantor Verlag. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 63 The aim of the present study was to compare the pharmacokinetic and pharmacodynamic properties of a fixed combination tablet contg. 10 mg of manidipine dihydrochloride (CAS 89226-75-5), a calcium channel antagonist, and 30 mg of delapril hydrochloride (CAS 83435-67-0), an angiotensin converting enzyme (ACE) inhibitor, during once daily repeated dosing in young and elderly subjects and to assess the bioequivalence of the fixed combination tablet and the single ingredient tablets taken simultaneously in young healthy subjects after a single dose administration. Eighteen young healthy male volunteers received a single oral dose of 10 mg manidipine and 30 mg delapril as two sep. tablets or a fixed combination tablet, followed by a week of once daily dosing with the fixed combination. Eight male and eight female elderly volunteers also received a week of once daily dosing with the fixed combination. Blood samples were collected during 24 h on the first and last treatment day for plasma detn. of manidipine, delapril and their main metabolites, using specific LC-MS/MS methods. Blood pressure and heart rate were also recorded during 24 h. Bioequivalence was strictly demonstrated between the extemporaneous and the fixed combination tablet after single dose administration. At steady-state in young subjects, manidipine AUC and Cmax were lower (-8 and -12 %) and t1/2 was longer (+ 45 %), while delapril and metabolites were little affected as compared to single dose. In elderly subjects, manidipine Cmax was 4 % lower than after single dose, AUC was 13 % higher, and t1/2 was increased 2.4-fold. For delapril and active metabolites, Cmax and AUC increased modestly. Blood pressure and heart rate vs. time profiles after single dose and at steady-state were almost superimposable. In elderly compared to young subjects at steady-state, peak concns. of manidipine and delapril changed by + 35 % and -15 % while AUCs increased by + 70 % and + 9.7 %. The fixed combination tablet of 10 mg manidipine and 30 mg delapril is bioequivalent to mono-ingredient tablets. At steady-state, the pharmacokinetic and pharmacodynamic profiles in young and elderly subjects undergo minor changes and indicate negligible accumulation. Drug exposure is higher in elderly subjects.